Table 2.
Unconditional Logistic Regression of Serum and Plasma Hormone Levels and Male Breast Cancer Risk
| Variable | Controls | Cases | OR* | 95% CI | P | Controls | Cases | OR† | 95% CI | P |
|---|---|---|---|---|---|---|---|---|---|---|
| DHEA, nmol/L | ||||||||||
| < 3.96 | 54 | 31 | 1.00 | Referent | 50 | 30 | 1.00 | Referent | ||
| 3.96 to < 6.07 | 54 | 21 | 0.67 | 0.34 to 1.35 | .27 | 51 | 20 | 0.68 | 0.34 to 1.39 | .29 |
| 6.07 to < 9.44 | 54 | 27 | 0.86 | 0.42 to 1.76 | .67 | 53 | 23 | 0.77 | 0.36 to 1.62 | .49 |
| ≥ 9.44 | 54 | 22 | 0.71 | 0.33 to 1.50 | .37 | 45 | 19 | 0.74 | 0.34 to 1.62 | .45 |
| Continuous | 216 | 101 | 0.90 | 0.60 to 1.33 | .58 | 199 | 92 | 0.90 | 0.58 to 1.40 | .65 |
| Androstenediol, pmol/L | ||||||||||
| < 2,040.95 | 54 | 24 | 1.00 | Referent | 49 | 21 | 1.00 | Referent | ||
| 2,040.95 to < 2,866.19 | 54 | 25 | 1.09 | 0.55 to 2.16 | .82 | 52 | 25 | 1.20 | 0.59 to 2.45 | .61 |
| 2866.19 to > 4,093.17 | 54 | 26 | 1.15 | 0.57 to 2.33 | .69 | 52 | 22 | 1.09 | 0.52 to 2.29 | .82 |
| ≥ 4,093.17 | 54 | 26 | 1.13 | 0.55 to 2.32 | .73 | 46 | 24 | 1.35 | 0.63 to 2.89 | .44 |
| Continuous | 216 | 101 | 1.04 | 0.64 to 1.70 | .88 | 199 | 92 | 1.28 | 0.75 to 2.20 | .37 |
| Androstenedione, nmol/L | ||||||||||
| < 1.95 | 55 | 20 | 1.00 | Referent | 54 | 19 | 1.00 | Referent | ||
| 1.95 to < 2.60 | 53 | 27 | 1.42 | 0.71 to 2.83 | .32 | 47 | 27 | 1.64 | 0.81 to 3.33 | .17 |
| 2.60 to < 3.41 | 54 | 34 | 1.71 | 0.87 to 3.36 | .12 | 48 | 28 | 1.65 | 0.81 to 3.35 | .17 |
| ≥ 3.41 | 54 | 20 | 0.99 | 0.47 to 2.07 | .98 | 50 | 18 | 1.00 | 0.46 to 2.16 | 1.00 |
| Continuous | 216 | 101 | 1.04 | 0.64 to 1.70 | .88 | 199 | 92 | 0.85 | 0.48 to 1.50 | .57 |
| Testosterone, nmol/L | ||||||||||
| < 10.05 | 55 | 21 | 1.00 | Referent | 52 | 19 | 1.00 | Referent | ||
| 10.05 to < 13.17 | 54 | 20 | 0.92 | 0.44 to 1.91 | .82 | 51 | 19 | 0.97 | 0.45 to 2.09 | .94 |
| 13.17 to < 16.41 | 54 | 28 | 1.30 | 0.65 to 2.59 | .46 | 49 | 26 | 1.39 | 0.67 to 2.88 | .38 |
| ≥ 16.41 | 53 | 32 | 1.49 | 0.75 to 2.95 | .25 | 47 | 28 | 1.53 | 0.73 to 3.17 | .26 |
| Continuous | 216 | 101 | 1.17 | 0.68 to 2.02 | .57 | 199 | 92 | 1.18 | 0.64 to 2.17 | .59 |
| DHT, pmol/L | ||||||||||
| < 1,070.34 | 55 | 22 | 1.00 | Referent | 51 | 20 | 1.00 | Referent | ||
| 1,070.34 to < 1,391.97 | 54 | 25 | 1.12 | 0.56 to 2.24 | .74 | 50 | 24 | 1.20 | 0.58 to 2.46 | .62 |
| 1,391.97 to < 1,800.11 | 54 | 25 | 1.13 | 0.57 to 2.26 | .72 | 49 | 21 | 1.04 | 0.50 to 2.18 | .92 |
| ≥ 1,800.11 | 53 | 29 | 1.34 | 0.68 to 2.62 | .40 | 49 | 27 | 1.31 | 0.64 to 2.70 | .46 |
| Continuous | 216 | 101 | 1.17 | 0.75 to 1.83 | .48 | 199 | 92 | 1.20 | 0.73 to 1.94 | .47 |
| 3α-diol-3G, nmol/L | ||||||||||
| < 2.23 | 54 | 32 | 1.00 | Referent | 51 | 30 | 1.00 | Referent | ||
| 2.23 to < 3.01 | 56 | 24 | 0.71 | 0.37 to 1.37 | .30 | 54 | 20 | 0.63 | 0.32 to 1.26 | .19 |
| 3.01 to < 4.40 | 52 | 23 | 0.74 | 0.38 to 1.45 | .38 | 47 | 21 | 0.81 | 0.40 to 1.63 | .55 |
| ≥ 4.40 | 54 | 22 | 0.67 | 0.34 to 1.34 | .26 | 47 | 21 | 0.80 | 0.39 to 1.63 | .53 |
| Continuous | 216 | 101 | 0.83 | 0.57 to 1.19 | .30 | 199 | 92 | 0.94 | 0.66 to 1.35 | .74 |
| 3α-diol-17G, nmol/L | ||||||||||
| < 4.49 | 54 | 23 | 1.00 | Referent | 49 | 20 | 1.00 | Referent | ||
| 4.49 to < 6.56 | 53 | 28 | 1.26 | 0.64 to 2.48 | .50 | 50 | 26 | 1.34 | 0.66 to 2.73 | .42 |
| 6.56 to < 9.24 | 55 | 29 | 1.25 | 0.63 to 2.47 | .52 | 51 | 26 | 1.34 | 0.65 to 2.78 | .43 |
| ≥ 9.24 | 53 | 20 | 0.89 | 0.43 to 1.84 | .76 | 48 | 19 | 1.06 | 0.49 to 2.29 | .89 |
| Continuous | 215 | 100 | 0.98 | 0.65 to 1.46 | .91 | 198 | 91 | 1.06 | 0.69 to 1.62 | .79 |
| ADT, pmol/L | ||||||||||
| < 493.66 | 55 | 29 | 1.00 | Referent | 51 | 27 | 1.00 | Referent | ||
| 493.66 to < 647.62 | 53 | 25 | 0.92 | 0.47 to 1.80 | .81 | 51 | 22 | 0.85 | 0.42 to 1.72 | .66 |
| 647.62 to < 874.96 | 54 | 25 | 0.90 | 0.46 to 1.75 | .75 | 50 | 24 | 0.93 | 0.47 to 1.86 | .84 |
| ≥ 874.96 | 54 | 22 | 0.83 | 0.41 to 1.71 | .62 | 47 | 19 | 0.84 | 0.39 to 1.81 | .65 |
| Continuous | 216 | 101 | 1.10 | 0.71 to 1.69 | .68 | 199 | 92 | 1.04 | 0.61 to 1.75 | .89 |
| ADT-G, nmol/L | ||||||||||
| < 54.96 | 53 | 31 | 1.00 | Referent | 49 | 30 | 1.00 | Referent | ||
| 54.96 to < 70.27 | 54 | 19 | 0.60 | 0.29 to 1.22 | .16 | 53 | 16 | 0.52 | 0.24 to 1.10 | .09 |
| 70.27 to < 101.09 | 54 | 30 | 0.94 | 0.48 to 1.82 | .85 | 49 | 27 | 0.95 | 0.47 to 1.89 | .88 |
| ≥ 101.09 | 54 | 20 | 0.64 | 0.30 to 1.35 | .24 | 47 | 18 | 0.69 | 0.31 to 1.50 | .35 |
| Continuous | 215 | 100 | 0.76 | 0.48 to 1.21 | .25 | 198 | 91 | 0.81 | 0.49 to 1.35 | .42 |
| Estrone, pmol/L | ||||||||||
| < 67.00 | 53 | 22 | 1.00 | Referent | 49 | 20 | 1.00 | Referent | ||
| 67.00 to < 84.45 | 53 | 21 | 0.94 | 0.46 to 1.93 | .87 | 47 | 19 | 0.96 | 0.45 to 2.05 | .92 |
| 84.45 to < 108.18 | 52 | 25 | 1.13 | 0.55 to 2.30 | .74 | 47 | 23 | 1.12 | 0.53 to 2.38 | .76 |
| ≥ 108.18 | 53 | 32 | 1.36 | 0.66 to 2.79 | .40 | 51 | 30 | 1.32 | 0.63 to 2.79 | .47 |
| Continuous | 211 | 100 | 1.22 | 0.69 to 2.17 | .49 | 194 | 92 | 1.17 | 0.65 to 2.10 | .60 |
| Estradiol, pmol/L | ||||||||||
| < 52.23 | 55 | 14 | 1.00 | Referent | 54 | 13 | 1.00 | Referent | ||
| 52.23 to < 65.98 | 54 | 22 | 1.58 | 0.73 to 3.43 | .25 | 47 | 17 | 1.50 | 0.66 to 3.44 | .34 |
| 65.98 to < 86.76 | 54 | 35 | 2.62 | 1.24 to 5.55 | .01 | 48 | 33 | 3.00 | 1.37 to 6.56 | .01 |
| ≥ 86.76 | 53 | 30 | 2.28 | 1.04 to 5.00 | .04 | 50 | 29 | 2.47 | 1.10 to 5.58 | .03 |
| Continuous | 216 | 101 | 1.68 | 0.95 to 2.99 | .08 | 199 | 92 | 1.79 | 0.98 to 3.25 | .06 |
Abbreviations: 3α-diol-3G, 3-androstanediol-3 glucuronide; 3α-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; OR, odds ratio.
*
Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and 25th centiles of distribution before correlative analysis.
†
Adjusted additionally for body mass index as continuous variable.